THE ROLE OF EPIGENETIC MECHANISMS IN ENDOCRINE DISORDERS
Keywords:
epigenetics, endocrine disorders, DNA methylation, histone modifications, microRNA, type 2 diabetes mellitus, obesity, polycystic ovary syndrome, autoimmune thyroid diseaseAbstract
Epigenetic mechanisms are increasingly recognized as important regulators of gene expression and potential contributors to the pathophysiology of endocrine disorders. These mechanisms influence cellular function without altering the underlying DNA sequence and include DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA-mediated regulation. Their activity is relevant to endocrine tissues, which must respond dynamically to developmental signals, metabolic demands, hormonal feedback, and environmental exposures. This narrative review examines the role of epigenetic regulation in type 2 diabetes mellitus, obesity, polycystic ovary syndrome, and autoimmune thyroid disease. Evidence from human studies and experimental research is considered, with particular attention to the distinction between disease-associated molecular changes and mechanisms that directly contribute to disease development. The review also discusses the potential applications of epigenetic biomarkers, their limitations, and emerging opportunities for targeted interventions. Current evidence supports the biological relevance of epigenetic regulation in endocrine pathophysiology; however, tissue specificity, methodological heterogeneity, and uncertainty regarding causality continue to limit clinical translation. Further longitudinal studies, functional experiments, and independent biomarker validation are required to establish the diagnostic and therapeutic value of epigenetic findings.
References
Zhang X, Ho SM. Epigenetics meets endocrinology. Journal of Molecular Endocrinology. 2011;46(1)–R32. https://doi.org/10.1677/JME-10-0053
Ho SM, Johnson A, Tarapore P, Janakiram V, Zhang X, Leung YK. Environmental epigenetics and its implication on disease risk and health outcomes. ILAR Journal. 2012;53(3–4):289–305. https://doi.org/10.1093/ilar.53.3-4.289
Nadiger N, Veed JK, Nataraj PC, Mukhopadhyay A. DNA methylation and type 2 diabetes: a systematic review. Clinical Epigenetics. 2024;16:67. https://doi.org/10.1186/s13148-024-01670-6
Saavedra LPJ, Piovan S, Moreira VM, et al. Epigenetic programming for obesity and noncommunicable disease: From womb to tomb. Reviews in Endocrine and Metabolic Disorders. 2024;25(2):309–324. https://doi.org/10.1007/s11154-023-09854-w
Chen Y, Wang G, Chen J, et al. Genetic and epigenetic landscape for drug development in polycystic ovary syndrome. Endocrine Reviews. 2024;45(4):437–459. https://doi.org/10.1210/endrev/bnae002
Wang B, Shao X, Song R, Xu D, Zhang J. The emerging role of epigenetics in autoimmune thyroid diseases. Frontiers in Immunology. 2017;8:396. https://doi.org/10.3389/fimmu.2017.00396
Tuli G, Munarin J, Davalos Flores KS, De Sanctis L. Insights into the genetic and epigenetic landscape of endocrine autoimmunity: A systematic review. Genes. 2025;16(12):1506. https://doi.org/10.3390/genes16121506
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in IQRO — Scientific Methodological Journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Authors retain copyright and grant the journal the right of first publication.
Users may read, download, copy, distribute, print, search, or link to the full texts of articles, provided that the original authors and the journal are properly cited.
Published materials may be used, distributed, and reproduced in any medium, provided that the original work is properly cited.



Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo